WHAT IS CLAIMED IS:

1. A peptide comprising 3-13 amino acids from residues 244-400 of SEQ ID NO:01 or from residues 1-150 of SEQ ID NO:750.

2. The peptide of claim 1, wherein the peptide is from the microtubule binding region (MTBR) of tau (residues 244-372 of SEQ ID NO:01).

3. The peptide of claim 1, wherein the peptide comprises an amino acid sequence selected from the group consisting of any one of SEQ ID NO:02 to SEQ ID NO:19, SEQ ID NO:25 to SEQ ID NO:320, SEQ ID NO:411, SEQ ID NO:454, SEQ ID NO:456, SEQ ID NO:458 to SEQ ID NO:742, SEQ ID NO:747 to SEQ ID NO:749, or SEQ ID NO:755 to SEQ ID NO:776.

4. The peptide of any one of claims 1-3, wherein the peptide further comprises a C-terminal cysteine (-C) or an N-terminal cysteine (C-).

5. The peptide of any one of claims 1-3, wherein the peptide further comprises a C-terminal -GGC or -GGGC and/or the peptide further comprises a N-terminal CGG or CGGG-.

6. The peptide of any one of claims 1-5, wherein the peptide comprises 7-13 amino acids from residues 244-400 of SEQ ID NO:01 or from residues 1-150 of SEQ ID NO:750.

7. The peptide of any one of claims 1-5, wherein the peptide comprises an amino acid sequence selected from the group consisting of any one of SEQ ID NO:777 to SEQ ID NO:908.

8. A peptide comprising an amino acid sequence selected from the group consisting of any one of SEQ ID NO:20 to SEQ ID NO:24, SEQ ID NO:312 to SEQ ID NO:457, each optionally further comprising a C-terminal cysteine.

9. The peptide of any one of claim 1, wherein the peptide comprises an amino acid sequence selected from the group consisting of

QIVYKPV	(SEQ ID NO:02),
QIVYKP	(SEQ ID NO:03),
NIKHVP	(SEQ ID NO:04),
NIKHVPG	(SEQ ID NO:05),
HVPGGG	(SEQ ID NO:06),
HVPGG	(SEQ ID NO:07),
HKPGGG	(SEQ ID NO:08),
HKPGG	(SEQ ID NO:09),
KHVPGGG	(SEQ ID NO:10),
KHVPGG	(SEQ ID NO:11),
HQPGGG	(SEQ ID NO:12),
HQPGG	(SEQ ID NO:13),
VQIINK	(SEQ ID NO:14),

VQIINKK (SEQ ID NO:15),
VQIINKKL (SEQ ID NO:16),
QIINK (SEQ ID NO:17),
QIINKK (SEQ ID NO:18),
QIINKKL (SEQ ID NO:19),
EIVYKSP (SEQ ID NO:25),
IVYKSPV (SEQ ID NO:26),
IVYK (SEQ ID NO:27),
QIVYKS (SEQ ID NO:325),
EIVYKS (SEQ ID NO:131),
EIVYKP (SEQ ID NO:411),
GYTMHQD (SEQ ID NO:454),
QGGYTMHQD (SEQ ID NO:456),
VKSKIGSTE (SEQ ID NO:589),
KSKIGSTE (SEQ ID NO:590),
SKIGSTEN (SEQ ID NO:598),
KIGSTENL (SEQ ID NO:605),
IGSTENLK (SEQ ID NO:611),
GSTENLKH (SEQ ID NO:616),
STENLKHQ (SEQ ID NO:620),
TENLKHQP (SEQ ID NO:476),
ENLKHQPG (SEQ ID NO:470),
VKSKIGST (SEQ ID NO:582),
PDLKNVKS (SEQ ID NO:755),
DLKNVKSK (SEQ ID NO:756),
LKNVKSKI (SEQ ID NO:757),
KNVKSKIG (SEQ ID NO:758),
NVKSKIGS (SEQ ID NO:759),
NLKHQPGG (SEQ ID NO:465),
LKHQPGGG (SEQ ID NO:460),
LDLSNVQS (SEQ ID NO:760),
DLSNVQSK (SEQ ID NO:761),
LSNVQSKC (SEQ ID NO:762),
SNVQSKCG (SEQ ID NO:763),
NVQSKCGS (SEQ ID NO:764),
VQSKCGSK (SEQ ID NO:626),
QSKCGSKD (SEQ ID NO:634),
SKCGSKDN (SEQ ID NO:642),
KCGSKDNI (SEQ ID NO:649),
CGSKDNIK (SEQ ID NO:258),
GSKDNIKH (SEQ ID NO:653),
SKDNIKHV (SEQ ID NO:271),
KDNIKHVP (SEQ ID NO:278),
DNIKHVPG (SEQ ID NO:285),
NIKHVPGG (SEQ ID NO:292),
IKHVPGGG (SEQ ID NO:297),

VDLSKVTS (SEQ ID NO:765),
DLSKVTSK (SEQ ID NO:766),
LSKVTSKC (SEQ ID NO:767),
SKVTSKCG (SEQ ID NO:768),
KVTSKCGS (SEQ ID NO:769),
VTSKCGSL (SEQ ID NO:770),
TSKCGSLG (SEQ ID NO:666),
SKCGSLGN (SEQ ID NO:674),
KCGSLGNI (SEQ ID NO:681),
CGSLGNIH (SEQ ID NO:687),
GSLGNIHH (SEQ ID NO:692),
SLGNIHHK (SEQ ID NO:696),
LGNIHHKP (SEQ ID NO:524),
GNIHHKPG (SEQ ID NO:518),
NIHHKPGG (SEQ ID NO:513),
IHHKPGGG (SEQ ID NO:508),
LDFKDRVQ (SEQ ID NO:771),
DFKDRVQS (SEQ ID NO:772),
FKDRVQSK (SEQ ID NO:773),
KDRVQSKI (SEQ ID NO:774),
DRVQSKIG (SEQ ID NO:775),
RVQSKIGS (SEQ ID NO:776),
VQSKIGSL (SEQ ID NO:702),
QSKIGSLD (SEQ ID NO:709),
SKIGSLDN (SEQ ID NO:717),
KIGSLDNI (SEQ ID NO:724),
IGSLDNIT (SEQ ID NO:729),
GSLDNITH (SEQ ID NO:734),
SLDNITHV (SEQ ID NO:738),
LDNITHVP (SEQ ID NO:561),
DNITHVPG (SEQ ID NO:555),
NITHVPGG (SEQ ID NO:551), and
ITHVPGGG (SEQ ID NO:547).

10. The peptide of claim 8, wherein the peptide comprises and amino acid sequence selected from the group consisting of

QIVYKSV (SEQ ID NO:20),
EIVYKSV (SEQ ID NO:21),
EIVYKPV (SEQ ID NO:22),
CNIKHVP (SEQ ID NO:23),
CNIKHVPG (SEQ ID NO:24),
EAAGHVTQC (SEQ ID NO:449),
EAAGHVTQAR (SEQ ID NO:450),
AAGHVTQAC (SEQ ID NO:451),
AGHVTQARC (SEQ ID NO:452),

AGHVTQAR (SEQ ID NO:453),
QGGYTMHC (SEQ ID NO:455), and
GGYTMHQC (SEQ ID NO:457).

11. The peptide of either one of claims 9 or 10, wherein the peptide further comprises a C-terminal cysteine (-C), -GGC or -GGGC or an N-terminal cysteine (C-), CGG- or CGGG-.

12. The peptide of claim 7, wherein the peptide comprises an amino acid sequence selected from the group consisting of

VKSKIGSTEGGC (SEQ ID NO:777),
KSKIGSTEGGC (SEQ ID NO:778),
SKIGSTENGGC (SEQ ID NO:779),
KIGSTENLGGC (SEQ ID NO:780),
IGSTENLKGGC (SEQ ID NO:781),
GSTENLKHGGC (SEQ ID NO:782),
STENLKHQGGC (SEQ ID NO:783),
TENLKHQPGGC (SEQ ID NO:784),
ENLKHQPGGGC (SEQ ID NO:785),
VKSKIGSTGGC (SEQ ID NO:786),
PDLKNVKSGGC (SEQ ID NO:787),
DLKNVKSKGGC (SEQ ID NO:788),
LKNVKSKIGGC (SEQ ID NO:789),
KNVKSKIGGGC (SEQ ID NO:790),
NVKSKIGSGGC (SEQ ID NO:791),
NLKHQPGGGGC (SEQ ID NO:792),
LKHQPGGGGGC (SEQ ID NO:793),
LDLSNVQSGGC (SEQ ID NO:794),
DLSNVQSKGGC (SEQ ID NO:795),
LSNVQSKCGGC (SEQ ID NO:796),
SNVQSKCGGGC (SEQ ID NO:797),
NVQSKCGSGGC (SEQ ID NO:798),
VQSKCGSKGGC (SEQ ID NO:799),
QSKCGSKDGGC (SEQ ID NO:800),
SKCGSKDNGGC (SEQ ID NO:801),
KCGSKDNIGGC (SEQ ID NO:802),
CGSKDNIKGGC (SEQ ID NO:803),
GSKDNIKHGGC (SEQ ID NO:804),
SKDNIKHVGGC (SEQ ID NO:805),
KDNIKHVPGGC (SEQ ID NO:806),
DNIKHVPGGGC (SEQ ID NO:807),
NIKHVPGGGGC (SEQ ID NO:808),
IKHVPGGGGGC (SEQ ID NO:809),
VDLSKVTSGGC (SEQ ID NO:810),
DLSKVTSKGGC (SEQ ID NO:811),
LSKVTSKCGGC (SEQ ID NO:812),

SKVTSKCGGGC (SEQ ID NO:813),
KVTSKCGSGGC (SEQ ID NO:814),
VTSKCGSLGGC (SEQ ID NO:815),
TSKCGSLGGGC (SEQ ID NO:816),
SKCGSLGNGGC (SEQ ID NO:817),
KCGSLGNIGGC (SEQ ID NO:818),
CGSLGNIHGGC (SEQ ID NO:819),
GSLGNIHHGGC (SEQ ID NO:820),
SLGNIHHKGGC (SEQ ID NO:821),
LGNIHHKPGGC (SEQ ID NO:822),
GNIHHKPGGGC (SEQ ID NO:823),
NIHHKPGGGGC (SEQ ID NO:824),
IHHKPGGGGGC (SEQ ID NO:825),
LDFKDRVQGGC (SEQ ID NO:826),
DFKDRVQSGGC (SEQ ID NO:827),
FKDRVQSKGGC (SEQ ID NO:828),
KDRVQSKIGGC (SEQ ID NO:829),
DRVQSKIGGGC (SEQ ID NO:830),
RVQSKIGSGGC (SEQ ID NO:831),
VQSKIGSLGGC (SEQ ID NO:832),
QSKIGSLDGGC (SEQ ID NO:833),
SKIGSLDNGGC (SEQ ID NO:834),
KIGSLDNIGGC (SEQ ID NO:835),
IGSLDNITGGC (SEQ ID NO:836),
GSLDNITHGGC (SEQ ID NO:837),
SLDNITHVGGC (SEQ ID NO:838),
LDNITHVPGGC (SEQ ID NO:839),
DNITHVPGGGC (SEQ ID NO:840),
NITHVPGGGGC (SEQ ID NO:841),
ITHVPGGGGGC (SEQ ID NO:842),
VKSKIGSTEGGGC (SEQ ID NO:851),
PDLKNVKSGGGC (SEQ ID NO:852),
DLKNVKSKGGGC (SEQ ID NO:853),
LKNVKSKIGGGC (SEQ ID NO:854),
KNVKSKIGGGGC (SEQ ID NO:855),
NVKSKIGSGGGC (SEQ ID NO:856),
VKSKIGSTEGGGC (SEQ ID NO:843),
KSKIGSTEGGGC (SEQ ID NO:844),
SKIGSTENGGGC (SEQ ID NO:845),
KIGSTENLGGGC (SEQ ID NO:846),
IGSTENLKGGGC (SEQ ID NO:847),
GSTENLKHGGGC (SEQ ID NO:848),
STENLKHQGGGC (SEQ ID NO:849),
TENLKHQPGGGC (SEQ ID NO:850),
ENLKHQPGGGGC (SEQ ID NO:857),
NLKHQPGGGGGC (SEQ ID NO:858),

LKHQPGGGGGGC (SEQ ID NO:859),
LDLSNVQSGGGC (SEQ ID NO:860),
DLSNVQSKGGGC (SEQ ID NO:861),
LSNVQSKCGGGC (SEQ ID NO:862),
SNVQSKCGGGGC (SEQ ID NO:863),
NVQSKCGSGGGC (SEQ ID NO:864),
VQSKCGSKGGGC (SEQ ID NO:865),
QSKCGSKDGGGC (SEQ ID NO:866),
SKCGSKDNGGGC (SEQ ID NO:867),
KCGSKDNIGGGC (SEQ ID NO:868),
CGSKDNIKGGGC (SEQ ID NO:869),
GSKDNIKHGGGC (SEQ ID NO:870),
SKDNIKHVGGGC (SEQ ID NO:871),
KDNIKHVPGGGC (SEQ ID NO:872),
DNIKHVPGGGGC (SEQ ID NO:873),
NIKHVPGGGGGC (SEQ ID NO:874),
IKHVPGGGGGGC (SEQ ID NO:875),
VDLSKVTSGGGC (SEQ ID NO:876),
DLSKVTSKGGGC (SEQ ID NO:877),
LSKVTSKCGGGC (SEQ ID NO:878),
SKVTSKCGGGGC (SEQ ID NO:879),
KVTSKCGSGGGC (SEQ ID NO:880),
VTSKCGSLGGGC (SEQ ID NO:881),
TSKCGSLGGGGC (SEQ ID NO:882),
SKCGSLGNGGGC (SEQ ID NO:883),
KCGSLGNIGGGC (SEQ ID NO:884),
CGSLGNIHGGGC (SEQ ID NO:885),
GSLGNIHHGGGC (SEQ ID NO:886),
SLGNIHHKGGGC (SEQ ID NO:887),
LGNIHHKPGGGC (SEQ ID NO:888),
GNIHHKPGGGGC (SEQ ID NO:889),
NIHHKPGGGGGC (SEQ ID NO:890),
IHHKPGGGGGGC (SEQ ID NO:891),
LDFKDRVQGGGC (SEQ ID NO:892),
DFKDRVQSGGGC (SEQ ID NO:893),
FKDRVQSKGGGC (SEQ ID NO:894),
KDRVQSKIGGGC (SEQ ID NO:895),
DRVQSKIGGGGC (SEQ ID NO:896),
RVQSKIGSGGGC (SEQ ID NO:897),
VQSKIGSLGGGC (SEQ ID NO:898),
QSKIGSLDGGGC (SEQ ID NO:899),
SKIGSLDNGGGC (SEQ ID NO:900),
KIGSLDNIGGGC (SEQ ID NO:901),
IGSLDNITGGGC (SEQ ID NO:902),
GSLDNITHGGGC (SEQ ID NO:903),
SLDNITHVGGGC (SEQ ID NO:904),

LDNITHVPGGGC (SEQ ID NO:905),
DNITHVPGGGGC (SEQ ID NO:906),
NITHVPGGGGGC (SEQ ID NO:907), and
ITHVPGGGGGGC (SEQ ID NO:908).

13. A peptide comprising 5-13 amino acids from residues 244-400 of SEQ ID NO:01 or from residues 1-150 of SEQ ID NO:750, comprising at least one amino acid substitution.

14. The peptide of claim 15, comprising an amino acid sequence of SKIGSTENLKH (SEQ ID NO:909)

15. The peptide of claim 15, wherein one of the at least one amino acid substitutions comprises an isoleucine substitution for a lysine at position 10.

16. The peptide of either one of claims 14 or 15, wherein one of the at least one amino acid substitutions comprises a lysine or leucine substitution for a tyrosine at position 6.

17. The peptide of any one of claims 14-16, wherein one of the at least one amino acid substitutions comprises an aspartic acid or glycine substitution for a glutamic acid at position 7.

18. The peptide of claim 14, wherein the peptide comprises an amino acid sequence selected from the group consisting of

SKIGSTENLKH (SEQ ID NO:909),
SKIGSTENIKH (SEQ ID NO:910),
SKIGSKDNLKH (SEQ ID NO:911),
SKIGSKENIKH (SEQ ID NO:912),
SKIGSLENLKH (SEQ ID NO:913),
SKIGSLENIKH (SEQ ID NO:914),
SKIGSTDNLKH (SEQ ID NO:915),
SKIGSTDNIKH (SEQ ID NO:916),
SKIGSKDNLKH (SEQ ID NO:917),
SKIGSKDNIKH (SEQ ID NO:918),
SKIGSLDNLKH (SEQ ID NO:919),
SKIGSLDNIKH (SEQ ID NO:920),
SKIGSTGNLKH (SEQ ID NO:921),
SKIGSTGNIKH (SEQ ID NO:922),
SKIGSKGNLKH (SEQ ID NO:923),
SKIGSKGNIKH (SEQ ID NO:924),
SKIGSLGNLKH (SEQ ID NO:925), and
SKIGSLGNIKH (SEQ ID NO:926).

19. The peptide of any one of claims 13-18, wherein the peptide further comprises a C-terminal cysteine (-C), -GGC or -GGGC or an N-terminal cysteine (C-), CGG- or CGGG-.

20. The peptide of claim 19, wherein the peptide comprises an amino acid sequence selected from the group consisting of

CGGGSKIGSTDNIKH (SEQ ID NO:966),
CGGGSKIGSKDNIKH (SEQ ID NO:967),
CGGGSKIGSLDNIKH (SEQ ID NO:968),
CGGSKIGSTDNIKH (SEQ ID NO:963),
CGGSKIGSKDNIKH (SEQ ID NO:964), and
CGGSKIGSLDNIKH (SEQ ID NO:965).

21. The peptide of claim 19, wherein the peptide comprises an amino acid sequence selected from the group consisting of

SKIGSTENLKHGGC (SEQ ID NO:927),
SKIGSTENIKHGGC (SEQ ID NO:928),
SKIGSKDNLKHGGC (SEQ ID NO:929),
SKIGSKENIKHGGC (SEQ ID NO:930),
SKIGSLENLKHGGC (SEQ ID NO:931),
SKIGSLENIKHGGC (SEQ ID NO:932),
SKIGSTDNLKHGGC (SEQ ID NO:933),
SKIGSTDNIKHGGC (SEQ ID NO:934),
SKIGSKDNLKHGGC (SEQ ID NO:935),
SKIGSKDNIKHGGC (SEQ ID NO:936),
SKIGSLDNLKHGGC (SEQ ID NO:937),
SKIGSLDNIKHGGC (SEQ ID NO:938),
SKIGSTGNLKHGGC (SEQ ID NO:939),
SKIGSTGNIKHGGC (SEQ ID NO:940),
SKIGSKGNLKHGGC (SEQ ID NO:941),
SKIGSKGNIKHGGC (SEQ ID NO:942),
SKIGSLGNLKHGGC (SEQ ID NO:943),
SKIGSLGNIKHGGC (SEQ ID NO:944),
SKIGSTENLKHGGGC (SEQ ID NO:945),
SKIGSTENIKHGGGC (SEQ ID NO:946),
SKIGSKDNLKHGGGC (SEQ ID NO:947),
SKIGSKENIKHGGGC (SEQ ID NO:948),
SKIGSLENLKHGGGC (SEQ ID NO:949),
SKIGSLENIKHGGGC (SEQ ID NO:950),
SKIGSTDNLKHGGGC (SEQ ID NO:951),
SKIGSTDNIKHGGGC (SEQ ID NO:952),
SKIGSKDNLKHGGGC (SEQ ID NO:953),
SKIGSKDNIKHGGGC (SEQ ID NO:954),
SKIGSLDNLKHGGGC (SEQ ID NO:955),
SKIGSLDNIKHGGGC (SEQ ID NO:956),
SKIGSTGNLKHGGGC (SEQ ID NO:957),
SKIGSTGNIKHGGGC (SEQ ID NO:958),
SKIGSKGNLKHGGGC (SEQ ID NO:959),

SKIGSKGNIKHGGGC (SEQ ID NO:960),
SKIGSLGNLKHGGGC (SEQ ID NO:961),
SKIGSLGNIKHGGGC (SEQ ID NO:962),
CGGSKIGSTDNIKH (SEQ ID NO:963),
CGGSKIGSKDNIKH (SEQ ID NO:964),
CGGSKIGSLDNIKH (SEQ ID NO:965),
CGGGSKIGSTDNIKH (SEQ ID NO:966),
CGGGSKIGSKDNIKH (SEQ ID NO:967), and
CGGGSKIGSLDNIKH (SEQ ID NO:968).

22. The peptide of any one of claims 1-21, further comprising a linker to a carrier at a C-terminal portion of the peptide or at a N-terminal portion of the peptide.

23. The peptide of claim 22, wherein the linker comprises an amino acid sequence.

24. The peptide of claim 23, wherein the linker amino acid sequence comprises between about 1-10 amino acids, about 1-9 amino acids, about 1-8 amino acids, about 1-7 amino acids, about 1-6 amino acids, about 1-5 amino acids, about 1-4 amino acids, about 1-3 amino acids, about 2 amino acids or one (1) amino acid.

25. The peptide of claim 23, wherein the linker comprises an amino acid sequence selected from the group consisting of AA, AAA, KK, KKK, SS, SSS AGAG, GG, GGG, GAGA, KGKG, (GGS)n, (GGGS)n, and (GGGGS)n, where n=1-3.

26. The peptide of any one of claims 1 to 25, wherein the peptide or linker to the carrier, if present, further comprises a C-terminal cysteine (C).

27. The peptide of any one of claims 1 to 26, wherein the peptide further comprises a blocked amine at the N-terminus.

28. An immunotherapy composition, comprising one or more of the peptides of any of claims 1 to 27.

29. The immunotherapy composition of claim 28, wherein the one or more peptides further comprises a linker to a carrier at a C-terminal portion of the peptide.

30. The immunotherapy composition of claim 29, wherein the linker to the carrier comprises an amino acid sequence selected from the group consisting of AA, AAA, KK, KKK, SS, SSS AGAG, GG, GGG, GAGA, KGKG, (GGS)n, (GGGS)n, and (GGGGS)n, where n=1-3.

31. The immunotherapy composition of either one of claims 29 or 30, wherein the carrier comprises serum albumins, immunoglobulin molecules, thyroglobulin, ovalbumin, tetanus toxoid (TT), diphtheria toxoid (DT), a genetically modified cross-reacting material (CRM) of diphtheria toxin, CRM197, meningococcal outer membrane protein complex (OMPC) and *H. influenzae* protein D (HiD), rEPA (*Pseudomonas aeruginosa* exotoxin A), KLH (keyhole limpet hemocyanin), and flagellin.

32. The immunotherapy composition of any one of claims 28-31, further comprising at least one pharmaceutically acceptable diluent.

33. The immunotherapy composition of any one of claims 28-32, further comprising a multiple antigen presenting system (MAP).

34 The immunotherapy composition of claim 33, wherein the MAP comprises one or more of a Lys-based dendritic scaffold, helper T-cell epitopes, immune stimulating lipophilic moieties, cell penetrating peptides, radical induced polymerization, self-assembling nanoparticles as antigen-presenting platforms and gold nanoparticles.

35. A pharmaceutical composition comprising (a) one or more of the peptides of any of claims 1 to 27 or (b) the immunotherapy composition of any of claims 28-34 and at least one adjuvant.

36. The pharmaceutical composition of claim 35, wherein the adjuvant is selected from the group consisting of aluminum hydroxide, aluminum phosphate, aluminum sulfate, 3 De-O-acylated monophosphoryl lipid A (MPL), QS-21, TQL-1055, QS-18, QS-17, QS-7, Complete Freund's Adjuvant (CFA), Incomplete Freund's Adjuvant (IFA), oil in water emulsions (such as squalene or peanut oil), CpG, polyglutamic acid, polylysine, AddaVax™, MF59®, and combinations thereof.

37. The pharmaceutical composition of claim 36, wherein the adjuvant is a combination of MPL and QS-21 or a combination of MPL and TQL-1055.

38. The pharmaceutical composition of claim 35, wherein the adjuvant comprises a liposomal formulation.

39. The pharmaceutical composition of any of claims 35-38, wherein the composition comprises at least one pharmaceutically acceptable diluent.

40. The pharmaceutical formulation of any of claims 35-39, comprising a multiple antigen presenting system (MAP).

41. The pharmaceutical formulation of claim 40, wherein the MAP comprises one or more of a Lys-based dendritic scaffold, helper T-cell epitopes, immune stimulating lipophilic moieties, cell penetrating peptides, radical induced polymerization, self-assembling nanoparticles as antigen-presenting platforms and gold nanoparticles.

42. A nucleic acid comprising a nucleic acid sequence encoding a peptide of any one of claims 1 to 28 or the immunotherapy composition of claims 28-34.

43. A nucleic acid immunotherapy composition comprising the nucleic acid of claim 42 and at least one adjuvant.

44. Use of the the immunotherapy composition of any of claims 28-34 or the pharmaceutical compositions of any of claims 35-41 in the manufacture of a medicament for treating or effecting prophylaxis of Alzheimer's disease in a subject.

45. Use of the immunotherapy composition of any of claims 28-34 or the pharmaceutical formulations of any of claims 35-41in the manufacture of a medicament for inhibiting or reducing aggregation of tau in a subject having or at risk of developing Alzheimer's disease.

46. Use of the nucleic acid immunotherapy composition of claim 43 in the manufacture of a medicament for treating or effecting prophylaxis of Alzheimer's disease in a subject.

47. Use of the nucleic acid immunotherapy composition of claim 43 in the manufacture of a medicament for inhibiting or reducing aggregation of tau in a subject having or at risk of developing Alzheimer's disease.

48. Use of any one of the peptide of claims 1-27, the immunotherapy composition of any of claims 28-34, the pharmaceutical formulations of any of claims 35-41 or the nucleic acid immunotherapy composition of claim 43 in the manufacture of a medicament for inducing an immune response in an animal, wherein the medicament is to be administered in a regimen effective to generate an immune response comprising antibodies that specifically bind to tau.

49. The use of claim 48, wherein the immune response comprises antibodies that specifically bind to the microtubule region of tau.

50. An immunization kit comprising the immunotherapy composition of any of claims 28-34.

51. The kit of claim 50, further comprising an adjuvant.

52. The kit of claim 51, wherein the immunotherapy composition is in a first container and the adjuvant is in a second container.

53. A kit comprising the nucleic acid immunotherapy composition of claim 43.

54. The kit of claim 53, further comprising an adjuvant.

55. The kit of claim 54, wherein the nucleic acid is in a first container and the adjuvant is in a second container.

56. The peptide of any one of claims 1-27, the immunotherapy composition of any one of claims 28-34, the pharmaceutical formulations of any of claims 35-41, or the nucleic acid immunotherapy composition of claim 43 for use in therapy.